Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial Networks

Clinical Infectious Diseases

Volumn 63, Issue , 2016, Pages S57-S59

  McDonnell, Anthony ^a   Rex, John H ^b,c   Goossens, Herman ^d   Bonten, Marc ^e   Fowler, Vance G ^f   Dane, Aaron ^b  

^a UK Review on Antimicrobial Resistance   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antibiotic development; antimicrobial resistance; trial networks

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL (TOPIC); HUMAN; INFECTION; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; REGISTRATION; RISK REDUCTION; STUDY DESIGN; COMMUNICABLE DISEASE; DRUG DEVELOPMENT; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROCEDURES;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASES; DRUG DISCOVERY; HUMANS; PATIENT OUTCOME ASSESSMENT; PRACTICE GUIDELINES AS TOPIC;

EID: 85010866375     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw244     Document Type: Article

References (17)

1. Review on Antimicrobial Resistance. Securing new drugs for future generations: the pipeline of antibiotics, 2015. Available at: http://amr-review.org/. Accessed 29 April 2016.
2. Sertkaya A, Eyraud J, Birkenbach A, et al. Analytical framework for examining the value of antibacterial products. Report to the US Department of Health and Human Services, 2014. Available at: http://aspe.hhs.gov/sp/reports/2014/antibacterials/rpt-antibacterials.cfm. Accessed 17 June 2014.
3. Kostyanev T, Bonten MJ, O'Brien S, et al. The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. J Antimicrob Chemother 2016; 71:290-5.
4. Rex JH, Eisenstein BI, Alder J, et al. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis 2013; 13:269-75.
5. US Food and Drug Administration. Guidance for industry: antibacterial therapies for patients with unmet medical need for the treatment of serious bacterial diseases. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed 29 April 2016.
6. European Medicines Agency, Committee for Medicinal Products for Human Use. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. EMA/CHMP/351889/2013. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/11/WC500153953.pdf. Accessed 1 May 2015.
7. Rex JH, Outterson K. Antibiotic reimbursement in a sales-delinked model: context and a benchmark-based global approach. Lancet Infect Dis 2016; 16:500-5.
8. Keat N, Law K, Seymour M, et al. International rare cancers initiative. Lancet Oncol 2013; 14:109-10.
9. Palmore TN, Henderson DK. Managing transmission of carbapenem-resistant Enterobacteriaceae in healthcare settings: a view from the trenches. Clin Infect Dis 2013; 57:1593-9.
10. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44:79-86.
11. Talbot GH, Powers JH, Hoffmann SC. Developing outcomes assessments as endpoints for registrational clinical trials of antibacterial drugs: 2015 update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin Infect Dis 2016; 62:603-7.
12. Food and Drug Administration, Center for Drug Evaluation. Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed 29 April 2016.
13. Food and Drug Administration, Center for Drug Evaluation. Guidance for industry (draft): community-acquired bacterial pneumonia: developing drugs for treatment. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed 29 April 2016.
14. Food and Drug Administration, Center for Drug Evaluation. Guidance for industry: hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia: developing drugs for treatment. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed 29 April 2016.
15. Food and Drug Administration, Center for Drug Evaluation. Guidance for industry: complicated intra-abdominal infections: developing drugs for treatment. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed 29 April 2016.
16. Food and Drug Administration, Center for Drug Evaluation. Guidance for industry: complicated urinary tract infections: developing drugs for treatment. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed 29 April 2016.
17. Odem-Davis K, Fleming TR. A simulation study evaluating bio-creep risk in serial non-inferiority clinical trials for preservation of effect. Stat Biopharm Res 2015; 7:12-24.